TY - JOUR
T1 - The diagnostic performance of patient symptoms in screening for COPD
AU - for the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network
AU - Johnson, Kate M.
AU - Tan, Wan C.
AU - Bourbeau, Jean
AU - Sin, Don D.
AU - Sadatsafavi, Mohsen
AU - Hamid, Qutayba
AU - Jabet, Carole
AU - Mancino, Palmina
AU - Li, Pei Zhi
AU - Song, Zhi
AU - Fortier, Yvan
AU - Benedetti, Andrea
AU - Jensen, Dennis
AU - Latreille, David
AU - Baril, Jacinthe
AU - Labonté, Laura
AU - Mark FitzGerald, J.
AU - Coxson, Harvey
AU - Marciniuk, Darcy
AU - Clemens, Ron
AU - Baran, Janet
AU - O'Donnell, Dennis E.
AU - O'Donnell, Denis
AU - McNeil, Matthew
AU - Whelan, Kate
AU - Hernandez, Paul
AU - Fulton, Scott
AU - Osterling, Kristen
AU - Chapman, Kenneth R.
AU - To, Teresa
AU - Gershon, Andrea
AU - Chapman, Kenneth
AU - McClean, Patricia
AU - Audisho, Nadeen
AU - Cowie, Robert
AU - Cowie, R.
AU - Walter, B.
AU - Cowie, Ann
AU - Dumonceaux, Curtis
AU - Machado, Lisette
AU - Aaron, Shawn
AU - Vandemheen, Kathy
AU - Pratt, Gay
AU - Bergeron, Amanda
AU - Maltais, F.
AU - Samet, Jonathon
AU - Puhan, Milo
AU - Lo, Christine
AU - Cheng, Sarah
AU - Fung, Cindy
N1 - Funding Information:
The current study was funded by a Canadian Lung Association Breathing as One Studentship Award and the Canadian Institutes of Health Research (application number 142238). The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN); industry partners: Astra Zeneca Canada Ltd.; Boehringer Ingelheim Canada Ltd.; GlaxoSmithKline Canada Ltd.; and Novartis. Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners are the CIHR (CIHR/Rx&D Collaborative Research Program Operating Grants 93326); the Respiratory Health Network of the Fonds de la recherche en santé du Québec (FRSQ); industry partners: Almirall; Merck Nycomed; Pfizer Canada Ltd.; and Theratechnologies. The funders had no role in study design, data collection and analysis, or preparation of the manuscript.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/8/3
Y1 - 2018/8/3
N2 - It is recommended that screening for COPD be restricted to symptomatic individuals, but supporting evidence is lacking. We determined the performance of wheeze, cough, phlegm, and dyspnea in discriminating COPD versus non-COPD in a population-based sample of 1332 adults. Area Under the Receiver Operating Curves (AUC) indicated that symptoms had modest performance whether assessed individually (AUCs 0.55-0.62), or in combination (AUC for number of symptoms as the predictor 0.64). AUC improved with the inclusion of multiple other factors (AUC 0.71). Restricting screening to symptomatic individuals is unlikely to substantially improve the yield of general population screening for undiagnosed COPD.
AB - It is recommended that screening for COPD be restricted to symptomatic individuals, but supporting evidence is lacking. We determined the performance of wheeze, cough, phlegm, and dyspnea in discriminating COPD versus non-COPD in a population-based sample of 1332 adults. Area Under the Receiver Operating Curves (AUC) indicated that symptoms had modest performance whether assessed individually (AUCs 0.55-0.62), or in combination (AUC for number of symptoms as the predictor 0.64). AUC improved with the inclusion of multiple other factors (AUC 0.71). Restricting screening to symptomatic individuals is unlikely to substantially improve the yield of general population screening for undiagnosed COPD.
UR - http://www.scopus.com/inward/record.url?scp=85051077871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051077871&partnerID=8YFLogxK
U2 - 10.1186/s12931-018-0853-5
DO - 10.1186/s12931-018-0853-5
M3 - Letter
C2 - 30075717
AN - SCOPUS:85051077871
SN - 1465-9921
VL - 19
JO - Respiratory Research
JF - Respiratory Research
IS - 1
M1 - 147
ER -